Recruiting

Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder

NCT06467461 · University of Minnesota

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study

This project will test the hypotheses that people with 5-HT RBD have systemic alpha- synuclein pathology, prodromal DLB signs, and brainstem lesions in regions that control REM sleep. AIM 1 will seek to detect abnormally phosphorylated alpha- synuclein aggregates on targeted skin biopsy in a cohort of people with 5-HT RBD and matched controls (taking SSRIs but without RBD). Aim 2 will use ultra-high field MRI at 7T to examine the pontine region of the coeruleus/subcoeruleus complex for evidence of neurodegeneration as well as segment and parcellate REM sleep related neuronal structures. Aim 3 will test for speech deficits. While these aims are independent we suspect that the severity of autonomic, speech and cognitive deficits will correlate with loss of neuromelanin signal on MRI and pathology on skin biopsy. The investigation is a longitudinal designed study to examine histopathology, neuroimaging changes and speech function from baseline (Time 1) to a follow-up after 30 months (Time 2). A total of 60 individuals, 30 with 5-HT RBD and 30 controls, will be recruited at Time 1, brought back at Time 2, and tested across all Aims at both study visits.

Eligibility criteria

Inclusion Criteria: Serotonergic REM sleep behavior (5-HT RBD) participants Inclusion Criteria: * Diagnosis of polysomnogram-confirmed RBD with history of dream enactment or clear dream enactment visualized on video from polysomnogram. * History of dream enactment began shortly after (less than 2 months) starting a serotonergic antidepressant medication. Control Participants Inclusion Criteria: * Age (±3 years) and sex matched to participants with 5-HT RBD * On serotonergic medication for at least 6 months without history of dream enactment. The following serotonergic medications will be included: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline Exclusion Criteria: Serotonergic REM sleep behavior (5-HT RBD) participants Exclusion Criteria: * Younger than 18 * Older than 75 * Meet criteria for Parkinson's disease, dementia with Lewy bodies, Multiple System Atrophy, Pure Autonomic Failure, Alzheimer's disease, other diagnosed neurodegenerative disorder, or other known cause of RBD (e.g. narcolepsy) * Untreated obstructive sleep apnea, obesity hypoventilation, central sleep apnea or other sleep disordered breathing * History of dysarthria, aphasia or other condition which could interfere with speech assessment * Reduced capacity to consent * MRI exclusion criteria for 7T scans: presence of any metallic clip(s) or implantable medical devices (e.g., heart valve, aneurysm clip, coils or surgery, renal or aortic clips, shunts, stents or stent grafts, metal mesh/coil implants, neurostimulator, insulin pump, IVC filter, etc.). * History of allergic response to xylocaine or other local anesthesia * Pregnant women will be excluded due to unknown risk of MRI on developing fetus Control Participants Exclusion Criteria: same exclusion criteria as 5-HT RBD group, plus the following: * History of dream enactment that may suggest RBD * Increased REM motor tone (REM atonia index \> 0.10) on PSG suggestive of RBD

Study design

Enrollment target: 60 participants

Allocation: na

Masking: none

Age groups: adult, older_adult

Timeline

Starts: 2024-02-08

Estimated completion: 2028-09-01

Last updated: 2025-07-08

Interventions

Diagnostic Test: Skin biopsyDiagnostic Test: Speech testingDiagnostic Test: Ultra high field 7T MRI

Primary outcomes

• Phosphorylated alpha synuclein deposits on skin biopsy (time point 1 (baseline) and time point 2 (24 months, +/- 3 months))
• Neuromelanin signal intensity in the Subcoeruleus/Coeruleus Complex (time point 1 (baseline) and time point 2 (24 months, +/- 3 months))
• Monopitch as measured by fundamental frequency variability. (time point 1 (baseline) and time point 2 (24 months, +/- 3 months))

Sponsor

University of Minnesota · other

Contacts & investigators

ContactJoy Schmidt · contact · schmidtj@umn.edu · (612) 624 -1456

InvestigatorMichael Howell, MD · principal_investigator, University of Minnesota

All locations (1)

University of MinnesotaRecruiting

Minneapolis, Minnesota, United States

View on ClinicalTrials.gov ↗Find similar trials